Skip to main content
Swing Capital

Aarti Pharmalabs Ltd

NSE: AARTIPHARM BSE: 543748

Incorporated in 2019, Aarti Pharmalabs Ltd is a manufacturer of Pharmaceuticals and Nutraceuticals[1]

₹697
52W: ₹584 — ₹972
PE 29.1 · Book ₹210 · +232% vs book
Market Cap₹6,315 Cr
Stock P/E29.1Price to Earnings
ROCE17.4%Return on Capital
ROE14.8%Return on Equity
Div. Yield0.71%Face Value ₹5

Strengths

  • +Company has delivered good profit growth of 564% CAGR over last 5 years

Weaknesses

  • −Company has a low return on equity of 13.6% over last 3 years.
  • −Company might be capitalizing the interest cost

Shareholding Pattern

Promoters43.08%
FIIs8.39%
DIIs7.4%
Public41.1%
CategoryJun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters46.46%46.1%▼0.444.65%▼1.544.29%▼0.443.72%▼0.642.88%▼0.843.1%▲0.243.08%▼0.0
FIIs7.07%7.38%▲0.38.64%▲1.37.36%▼1.37.34%▼0.08.02%▲0.77.69%▼0.38.39%▲0.7
DIIs11.47%11.35%▼0.110.36%▼1.07.53%▼2.87.8%▲0.36.95%▼0.87.66%▲0.77.4%▼0.3
Public35%35.17%▲0.236.33%▲1.240.81%▲4.541.12%▲0.342.12%▲1.041.54%▼0.641.1%▼0.4

Financial Statements

MetricSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales356373415393377471530375417425
Expenses282285307310293356386280343322
Operating Profit748810784851151439574103
OPM %21%24%26%21%22%24%27%25%18%24%
Net Profit42486347487489513144
EPS ₹4.615.326.955.25.288.119.85.653.414.84

AI Insights

Revenue Trend

TTM revenue at ₹1,747Cr, down 1.4% YoY. OPM at 24%.

Debt Position

Borrowings at ₹659Cr. Debt-to-equity ratio: 0.35x. Healthy balance sheet.

Capex Cycle

CWIP at ₹160Cr (11% of fixed assets). Moderate ongoing capital expenditure.

Institutional Flow

DIIs: 7.4% (-3.25pp change). FIIs: 8.39% (+0.96pp change). Promoters hold 43.08%.

Margin & Efficiency

ROCE improving from 0% (Mar 2020) to 17% (Mar 2025). Working capital days: 118.

Valuation

PE 29.1x with 17.4% ROCE. Price is 232% above book value of ₹210. Dividend yield: 0.71%.

Recent Announcements